Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Femring Articles

Watson to acquire US rights to Columbia Labs' Crinone and Prochieve for up to $92 million

5 March 2010

Battle for Warner Chilcott may continue

8 November 2004

Warner Chilcott's Femtrace cleared in USA

30 August 2004

UPDATE: Warner Chilcott's Femtrace OKed in USA

30 August 2004

Sales strong at Galen on acquisition spree, organic growth now sought

17 November 2003

UPDATE: Galen merger talks with Barr terminated as share price is driven higher

28 July 2003

Galen launches Femring in USA

23 June 2003

Stock Commentary - Europe

7 April 2003

Galen's Femring cleared by FDA

31 March 2003

Stock Commentary - Europe

31 March 2003

Galen gets US OK for Femring

31 March 2003

Galen seeking to buy Pfizer drugs for $359M

10 March 2003

Galen EPS leaps 35%, beating forecasts

17 February 2003

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS